Peptide data sheet
Tirzepatide
GLP-1 · Mounjaro · Zepbound · LY3298176
Verdict
promisingThe promising label reflects the large human trial program behind the branded prescription drugs Mounjaro and Zepbound; research-grade tirzepatide sold for lab use is not the same product and carries the gray-market sourcing risks the brand versions do not.
Quick answer
Tirzepatide is a dual GIP/GLP-1 receptor agonist commonly researched for weight and blood-sugar outcomes, with some of the strongest human trial data in its class. That data supported the FDA-approved prescription drugs Mounjaro and Zepbound for narrow indications; research-grade tirzepatide sold for lab use is not those products and is not FDA-approved. Gastrointestinal side effects are commonly reported, and the full safety picture outside supervised prescription use is still being studied.
- Class
- Dual GIP / GLP-1 receptor agonist (synthetic peptide)
- Half-life
- roughly 5 days (reported)
- FDA status
- Mounjaro and Zepbound (tirzepatide) are FDA-approved for narrow indications (type 2 diabetes; chronic weight management).
- WADA banned?
- No
Which form actually works?
Brand injectable (Mounjaro / Zepbound)
Promising
The trial-backed prescription form the pivotal human studies used, dispensed as Mounjaro or Zepbound under medical supervision. It carries the most research context and the clearest safety monitoring of any form.
Research-grade / gray-market vial
Risky
Sold for laboratory research use only, this is not the studied prescription product. Purity, sterility, and labeled strength are not verified by any regulator, and mislabeled or contaminated material is a documented gray-market hazard that no vial reveals on sight.